Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors

BACKGROUND AND OBJECTIVES: To describe the marked clinical and biological responses of a targeted treatment with anti–interleukin-6 (IL-6)–receptor antibody and Janus kinase (JAK) inhibitors in a patient with a severe, corticoresistant CNS toxicity of immune-checkpoint inhibitor (ICI) therapy. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Picca, Alberto, Valyraki, Nefeli, Birzu, Cristina, Kramkimel, Nora, Hermine, Olivier, Zahr, Noel, Berzero, Giulia, Psimaras, Dimitri
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Clinical/Scientific Notes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439960/
https://www.ncbi.nlm.nih.gov/pubmed/34497101
http://dx.doi.org/10.1212/NXI.0000000000001073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439960/
https://www.ncbi.nlm.nih.gov/pubmed/34497101
http://dx.doi.org/10.1212/NXI.0000000000001073

Ejemplares similares